Executive Summary
Summary Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutics (RCT) product candidates. Its products under development are intended for the treatment of phenylketonuria, refractory gout, homocystinuria, hyperoxaluria, R/R aPD1 solid tumor, acute myeloid leukemia (AML) post-allogeneic hematopoietic stem cell transplantation, cancer, pemphigus vulgaris and type 1 diabetes, among others. Rubius Therapeutics is headquartered in Cambridge, Massachusetts, the US. Rubius Therapeutics Inc (RUBY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios. - Business Description-A brief description of the company's operations. - Key Employees-A list of the key executives of the company. - Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors-A list of the key competitors of the company. - Key Recent Developments-A brief on recent news about the company. Reasons to buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents Table of Contents 3 List of Tables 4 List of Figures 4 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10 Venture Financing 10 Rubius Therapeutics Raises USD100 Million in Venture Financing 10 Rubius Therapeutics Raises Funds through Venture Financing 11 Rubius Therapeutics Raises USD120 Million in Venture Financing 12 Rubius Therapeutics Raises USD25 Million in Venture Financing 13 Licensing Agreements 14 Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14 Equity Offering 15 Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15 Rubius Therapeutics Inc-Key Competitors 16 Rubius Therapeutics Inc-Key Employees 17 Rubius Therapeutics Inc-Locations And Subsidiaries 18 Head Office 18 Recent Developments 19 Strategy And Business Planning 19 Sep 19, 2018: Raimondo, State officials break ground on new pharmaceutical manufacturing facility 19 Financial Announcements 20 Aug 31, 2018: Rubius Therapeutics announces second quarter 2018 financial results 20 Corporate Communications 21 Jun 06, 2018: Rubius Therapeutics Names Pablo J. Cagnoni As Chief Executive Officer 21 May 02, 2018: Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors 22 Feb 20, 2018: Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing 23 Feb 01, 2018: Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors 24 Dec 14, 2017: Rubius Therapeutics Strengthens Leadership Team with Appointment of Andrew Oh as Chief Financial Officer 25 Sep 27, 2017: Rubius Therapeutics Appoints Chief Medical Officer; Other Key Leadership Team Hires 26 Aug 08, 2017: Cell therapy pioneer David Epstein expands role with Rubius Therapeutics to become executive chairman 27 Jan 04, 2017: Rubius Therapeutics Announces Appointment of Top Leadership 28 Legal and Regulatory 29 Sep 14, 2018: Rubius Therapeutics added to Russell 2000 and 3000 indexes 29 Appendix 30 Methodology 30 About GlobalData 30 Contact Us 30 Disclaimer 30
List of Tables Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Rubius Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8 Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 Rubius Therapeutics Raises USD100 Million in Venture Financing 10 Rubius Therapeutics Raises Funds through Venture Financing 11 Rubius Therapeutics Raises USD120 Million in Venture Financing 12 Rubius Therapeutics Raises USD25 Million in Venture Financing 13 Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14 Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15 Rubius Therapeutics Inc, Key Competitors 16 Rubius Therapeutics Inc, Key Employees 17
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Rubius Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
